Zhong J - Search Results

1

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).

Simpson EL, Forman S, Silverberg JI, Zirwas M, Maverakis E, Han G, Guttman-Yassky E, Marnell D, Bissonnette R, Waibel J, Nunes FP, DeLozier AM, Angle R, Gamalo M, Holzwarth K, Goldblum O, Zhong J, Janes J, Papp K. Simpson EL, et al. Among authors: zhong j. J Am Acad Dermatol. 2021 Jul;85(1):62-70. doi: 10.1016/j.jaad.2021.02.028. Epub 2021 Feb 16. J Am Acad Dermatol. 2021. PMID: 33600915 Clinical Trial.

2

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.

Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB. Taylor PC, et al. Among authors: zhong j. Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20. Ann Rheum Dis. 2018. PMID: 29463520 Free PMC article. Review.

3

Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials.

Chen YC, Yoo DH, Lee CK, Li KJ, Won JE, Wu WS, Zhong J, Nicolay C, Walls CD, Tanaka Y. Chen YC, et al. Among authors: zhong j. Int J Rheum Dis. 2020 Jan;23(1):65-73. doi: 10.1111/1756-185X.13748. Epub 2019 Nov 14. Int J Rheum Dis. 2020. PMID: 31729189 Clinical Trial.

4

An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis.

Werfel T, Irvine AD, Bangert C, Seneschal J, Grond S, Cardillo T, Brinker D, Zhong J, Riedl E, Wollenberg A. Werfel T, et al. Among authors: zhong j. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1486-1496. doi: 10.1111/jdv.18193. Epub 2022 May 18. J Eur Acad Dermatol Venereol. 2022. PMID: 35490395

5

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.

Kremer JM, Schiff M, Muram D, Zhong J, Alam J, Genovese MC. Kremer JM, et al. Among authors: zhong j. RMD Open. 2018 Jan 13;4(1):e000581. doi: 10.1136/rmdopen-2017-000581. eCollection 2018. RMD Open. 2018. PMID: 29479473 Free PMC article.

6

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids.

van Vollenhoven R, Helt C, Arora V, Zhong J, Correia AP, de la Torre I, Muram D. van Vollenhoven R, et al. Among authors: zhong j. Rheumatol Ther. 2018 Dec;5(2):525-536. doi: 10.1007/s40744-018-0128-0. Epub 2018 Oct 24. Rheumatol Ther. 2018. PMID: 30357613 Free PMC article.

7

Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib.

Combe B, Balsa A, Sarzi-Puttini P, Tony HP, de la Torre I, Rogai V, Durand F, Witt S, Zhong J, Dougados M. Combe B, et al. Among authors: zhong j. Ann Rheum Dis. 2019 Aug;78(8):1135-1138. doi: 10.1136/annrheumdis-2018-214261. Epub 2019 Mar 6. Ann Rheum Dis. 2019. PMID: 30842122 Free PMC article. No abstract available.

8

Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis.

Genovese MC, Smolen JS, Takeuchi T, Burmester G, Brinker D, Rooney TP, Zhong J, Daojun M, Saifan C, Cardoso A, Issa M, Wu WS, Winthrop KL. Genovese MC, et al. Among authors: zhong j. Lancet Rheumatol. 2020 Jun;2(6):e347-e357. doi: 10.1016/S2665-9913(20)30032-1. Lancet Rheumatol. 2020. PMID: 38273598

9

Clinical and laboratory characteristics of Sjögren's syndrome-associated autoimmune liver disease: a real-world, 10-year retrospective study.

Liang P, Huang Y, Hu Z, Zhou L, Cai S, Zhong J, Dong L. Liang P, et al. Among authors: zhong j. Clin Rheumatol. 2025 Jan 18. doi: 10.1007/s10067-024-07273-z. Online ahead of print. Clin Rheumatol. 2025. PMID: 39826046

10

Immune-cell signatures of persistent inflammation, immunosuppression, and catabolism syndrome after sepsis.

Sun XF, Luo WC, Huang SQ, Zheng YJ, Xiao L, Zhang ZW, Liu RH, Zhong ZW, Song JQ, Nan K, Qiu ZX, Zhong J, Miao CH. Sun XF, et al. Among authors: zhong j. Med. 2025 Jan 9:S2666-6340(24)00483-5. doi: 10.1016/j.medj.2024.12.003. Online ahead of print. Med. 2025. PMID: 39824181

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,108 results

Search Page

Filters